Trial Profile

A Phase 1/2a Study of Subretinal Administration of OpCT-001 Photoreceptor Precursor Cells Derived From iPSCs in Patients With Primary Photoreceptor Disease

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OpCT 001 (Primary)
Indications Retinal disorders; Retinitis pigmentosa
Focus Adverse reactions; First in man
Acronyms CLARICOR
Sponsors BlueRock Therapeutics

Most Recent Events

22 Jan 2026 According to a BlueRock Therapeutics media release,company announced that its investigational cell therapy, OpCT-001, has received Orphan Drug Designation from the U.S. FDA for treating retinitis pigmentosa (RP).
08 Jul 2025 According to a BlueRock Therapeutics media release, First patient has been dosed in this trial.
18 Mar 2025 Planned End Date changed from 1 Aug 2030 to 1 Oct 2030.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com